![Detlev Mennerich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Detlev Mennerich
Direktor/Vorstandsmitglied bei
NBE-Therapeutics AG
Profil
Detlev Mennerich is currently Director at NBE-Therapeutics AG, TACALYX GmbH, and T-Knife GmbH.
Formerly, Dr. Mennerich was Corporate Senior Vice President at Boehringer Ingelheim International GmbH from 2022 to 2025, Director at Rinri Therapeutics Ltd., and Chairman-Supervisory Board at Topas Therapeutics GmbH.
Education includes an undergraduate degree from Technische Universität Braunschweig in 1997 and a doctorate from Martin-Luther-Universität Halle-Wittenberg in 2000.
Aktive Positionen von Detlev Mennerich
| Unternehmen | Position | Beginn |
|---|---|---|
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Private Equity Investor | 01.01.2014 |
TACALYX GmbH
 TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services Develops therapeutics targeting cancer-specific carbohydrate antigens for metastatic malignant tumors | Direktor/Vorstandsmitglied | - |
NBE-Therapeutics AG
 NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Direktor/Vorstandsmitglied | - |
T-Knife GmbH
 T-Knife GmbH BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops novel therapeutics to fight cancer | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Detlev Mennerich
| Unternehmen | Position | Ende |
|---|---|---|
Boehringer Ingelheim International GmbH
 Boehringer Ingelheim International GmbH Pharmaceuticals: MajorHealth Technology Engages in development, manufacturing and marketing of medicines for humans & animals | Corporate Officer/Principal | 01.01.2025 |
Topas Therapeutics GmbH
 Topas Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for immune tolerance | Vorsitzender | - |
Rinri Therapeutics Ltd.
 Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops regenerative stem cell-based therapies for treatment of hearing loss | Direktor/Vorstandsmitglied | - |
Ausbildung von Detlev Mennerich
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
76
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Technische Universität Braunschweig
 Technische Universität Braunschweig Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Martin-Luther-Universität Halle-Wittenberg
 Martin-Luther-Universität Halle-Wittenberg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH Pharmaceuticals: MajorHealth Technology Engages in development, manufacturing and marketing of medicines for humans & animals | Health Technology |
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Finance |
NBE-Therapeutics AG
NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Health Technology |
Topas Therapeutics GmbH
Topas Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for immune tolerance | Health Technology |
Rinri Therapeutics Ltd.
Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops regenerative stem cell-based therapies for treatment of hearing loss | Commercial Services |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services Develops therapeutics targeting cancer-specific carbohydrate antigens for metastatic malignant tumors | Commercial Services |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops novel therapeutics to fight cancer | Health Technology |
